RAPT Q2 2021 Earnings Report
Key Takeaways
RAPT Therapeutics reported a net loss of $16.1 million for the second quarter of 2021, compared to a net loss of $12.4 million for the same period in 2020. The company highlighted positive results from a Phase 1b clinical trial and the closing of a public offering that increased their cash reserves.
Announced positive topline results from Phase 1b clinical trial of RPT193 in atopic dermatitis.
Closed an underwritten public offering with net proceeds of $134.6 million.
Demonstrated early proof-of-concept for RPT193 and FLX475 in atopic dermatitis and cancer, respectively.
Well positioned to advance product development efforts and report additional data.
RAPT
RAPT
Forward Guidance
This press release contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements.